Login to Your Account

First in the U.S.? BLA filing due next year

Spark Therapeutics Inc.'s pleasing phase III top-line data with its compound for blindness-causing, RPE65-mediated, IRDs whetted investor appetite for more-detailed results and sent hope surging through the sector.more »

Our Habitat for All Things Science
Vaccines are bright spot in infectious disease fight

SAN DIEGO – Predictions at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting tend to be of the dire sort, warning of a return to the pre-penicillin era. So it was a pleasant exception to listen to Glaxosmithkline plc's Rino Rappuoli brim with optimism during his plenary talk on challenges and opportunities of vaccines.



Partners in Focus